Clinical Trials Logo

Clinical Trial Summary

This is a first-in-human, multi-center clinical study to determine the safety, Maximum Tolerated Dose (MTD) and/or Optimal Biological Dose (OBD) as well as the optimal schedule for intravenous (IV) and/or subcutaneous (SC) administrations of RO7293583 with or without obinutuzumab pretreatment, in participants with unresectable metastatic TYRP1-positive melanomas who have progressed on standard of care (SOC) treatment, are intolerant to SOC, or are non-amenable to SOC. This study will include an initial single participant dose-escalation part one followed by a multiple participant dose-escalation part two with the possibility of expansion.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04551352
Study type Interventional
Source Hoffmann-La Roche
Status Completed
Phase Phase 1
Start date October 28, 2020
Completion date July 28, 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04364230 - Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) Phase 1/Phase 2
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Active, not recruiting NCT05542342 - Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. Phase 2
Completed NCT02849145 - Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0) N/A
Recruiting NCT01438658 - Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma N/A
Not yet recruiting NCT00811200 - Treatment Of Radiation Retinopathy Trial Phase 2/Phase 3
Completed NCT00121225 - Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma Phase 2
Recruiting NCT05077280 - A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma Phase 2
Completed NCT03297424 - A Study of PLX2853 in Advanced Malignancies. Phase 1
Withdrawn NCT05482074 - Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 Phase 2
Not yet recruiting NCT06246149 - Adjuvant Tebentafusp in High Risk Ocular Melanoma Phase 3
Completed NCT01955941 - Vascular Response to Brachytherapy Using Functional OCT
Completed NCT00661622 - Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF Phase 2
Recruiting NCT05502900 - Adjuvant Melatonin for Uveal Melanoma Phase 3
Active, not recruiting NCT03070392 - Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma Phase 2
Recruiting NCT06284512 - Uveal Melanoma - Comparative Study
Recruiting NCT05524935 - Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma Phase 2
Active, not recruiting NCT02913417 - Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases Phase 1/Phase 2
Not yet recruiting NCT06073548 - Patient Experience and Quality of Life During the Surveillance Phase of Uveal Melanoma: A Prospective Multi-method Study
Recruiting NCT06075589 - Psychoeducation for Uveal Melanoma